Japan Based Daiichi Sankyo Company, Limited Announced That It Has Entered Into A Clinical Trial Collaboration Agreement With A Subsidiary Of Merck &Amp; Co., Inc., Kenilworth, New Jersey, U.S.A., Known As Msd Outside The United States And Canada, To Evaluate The Combination Of Ds-1062, A Trop2 Directed Dxd Antibody Drug Conjugate (Adc), And Keytruda&Reg; (Pembrolizumab) In Patients With Previously-Treated Advanced Or Metastatic Non-Small Cell Lung Cancer (Nsclc) Without Actionable Genomic Alterations.Trop2 (Trophoblast Cell-Surface Antigen 2) Is A Transmembrane Glycoprotein That Is Overexpressed In Many Cancers; High Trop2 Expression Has Been Identified In A Majority Of Nsclcs.Under The Terms Of The Agreement, Daiichi Sankyo Will Conduct A Multicenter, Two-Part, Open-Label, Non-Randomized, Phase 1B Study Of Ds-1062 In Combination With Keytruda In Patients With Advanced Or Metastatic Nsclc Without Actionable Genomic Alterations And Previously Treated With Platinum-Based Chemotherapy With Or Without Immunotherapy.Ds-1062 Is One Of Three Lead Dxd Antibody Drug Conjugates (Adcs) In The Oncology Pipeline Of Daiichi Sankyo.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!